The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent.
